United States · FDA National Drug Code directory
VIMIZIM
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 68135-100_d3f50b07-ab7c-4922-83b5-6441be0c3c11
- Product NDC
- 68135-100
- Form
- INJECTION, SOLUTION, CONCENTRATE
- Composition / generic term
- elosulfase alfa
- Labeler
- BioMarin Pharmaceutical Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20140214
- Source listing expiry
- 20261231
Source-listed ingredients
- ELOSULFASE ALFA — 5 mg/5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL in 1 CARTON (68135-100-01) / 5 mL in 1 VIAL · 68135-100-01
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →